-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![frontiers 2021 featured](https://volition.com/wp-content/uploads/2024/02/frontiers-2021-featured-e1708101123630.jpg)
Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression
- Share
- Tweet
- Share on Facebook
- Share
![Frontiers 2021 thumbnail](https://volition.com/wp-content/uploads/2024/02/Frontiers-2021-thumbnail.jpg)
![Frontiers 2021 thumbnail](https://volition.com/wp-content/uploads/2024/02/Frontiers-2021-thumbnail.jpg)
Paper titled: ‘Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression.’
Published in Frontiers in Molecular Biosciences 2021
Cavalier et al
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields